Cancer patients rank Janssen top for corporate reputation

A comprehensive survey of cancer patient groups has ranked Janssen, the pharma arm of Johnson & Johnson (NYSE: JNJ), as the top oncology firm for corporate reputation in 2018.

The seventh annual  iteration of “The Corporate Reputation of Pharma — Cancer Edition,” draws conclusions from a survey of 139 patient groups from 57 countries, 62% of which are national patient groups and 11% of which are international patient groups.

In the survey, Takeda (TYO: 4502) was the biggest riser in corporate reputation, jumping 15 places to fifth. France’s Servier jumped 11 places to overall 17th in 2018.